COVID-19 Vaccination Coverage and Associated Factors in Patients with Multiple Sclerosis.

Publication date: Jan 26, 2024

Our objective was to know the COVID-19 vaccination coverage in multiple sclerosis (MS) patients and its factors associated. A retrospective cohort study was carried out. Patients seen at the MS unit of the University Clinical Hospital of Zaragoza between 2017 and 2021 were included. Variables were obtained by reviewing the specialized and primary care records. Associations between receiving COVID-19 full primo-vaccination, as well as one booster dose since autumn 2022, and the other variables were analyzed using bivariate analysis and multiple logistic regression models. Of the 359 included patients, 90. 3% received the COVID-19 full primo-vaccination. Having been born in Spain (OR = 3. 40) and having received the 2020-2021 influenza vaccine (OR = 6. 77) were associated with receiving the COVID-19 full primo-vaccination. Vaccination with a COVID-19 booster dose was detected in 141 patients (39. 3%). Sex (man) (OR = 2. 36), age (60 years or over) (OR = 6. 82), type of MS (Primary Progressive/Secondary Progressive) (OR = 3. 94), and having received the 2022-2023 influenza vaccine (OR = 27. 54) were associated with receiving such a booster dose. The COVID-19 booster dose was administered at the same time as the 2022-2023 influenza vaccine in 57. 8% (67/116) of the patients vaccinated with both vaccines. The COVID-19 full primo-vaccination coverage is higher than in other countries. However, the decrease in vaccination coverage with the booster dose makes it necessary to develop strategies to improve it that are not limited to administering the flu vaccine together with the COVID-19 booster dose. Such strategies should be in focus, especially for women under 60 years of age.

Open Access PDF

Concepts Keywords
Basel associated factors
Sclerosis COVID-19 booster dose
Spain COVID-19 full primo-vaccination
Vaccinated COVID-19 vaccines
multiple sclerosis
vaccination coverage
vaccination strategies


Type Source Name
disease MESH COVID-19
disease VO vaccination coverage
disease MESH Multiple Sclerosis
disease VO vaccination
disease VO dose
disease MESH influenza
disease VO vaccine
disease VO time
disease VO vaccinated
disease VO population
drug DRUGBANK Polyethylene glycol
disease MESH respiratory infections
drug DRUGBANK Dimethyltryptamine
pathway REACTOME Immune System
disease MESH infections
disease IDO infection
drug DRUGBANK Coenzyme M
disease VO effective
drug DRUGBANK Etoperidone
disease VO Comirnaty
disease VO USA
disease VO vaccine dose
disease VO subunit vaccine
disease MESH allergy
disease MESH infectious diseases
disease MESH death
disease IDO country
disease MESH complications
disease MESH cardiovascular disease
disease MESH diabetes mellitus
disease MESH morbid obesity
disease MESH nephrotic syndrome
disease MESH hemoglobinopathies
disease MESH anemias
disease MESH hemophilia
disease MESH bleeding
disease IDO blood
disease MESH liver disease
disease MESH neuromuscular diseases
disease IDO immunosuppression
disease MESH cancer
disease MESH fistula
disease MESH celiac disease
disease MESH Crohn’s disease
disease MESH ulcerative colitis
disease MESH juvenile arthritis
disease MESH Syndrome
disease MESH dementia
disease VO pregnant women
drug DRUGBANK Pentaerythritol tetranitrate
disease VO protocol
disease VO influenza vaccines
disease IDO history
disease VO age

Original Article

(Visited 1 times, 1 visits today)